Edition:
United Kingdom

Amyris Inc (AMRS.OQ)

AMRS.OQ on NASDAQ Stock Exchange Global Select Market

4.09USD
14 Dec 2018
Change (% chg)

$-0.12 (-2.85%)
Prev Close
$4.21
Open
$4.20
Day's High
$4.23
Day's Low
$3.98
Volume
361,614
Avg. Vol
319,817
52-wk High
$9.28
52-wk Low
$3.19

Latest Key Developments (Source: Significant Developments)

Amyris Sells $60 Mln Unsecured Convertible Senior Notes
Friday, 7 Dec 2018 

Dec 7 (Reuters) - Amyris Inc ::HAS ENTERED INTO DEFINITIVE AGREEMENTS FOR SALE OF $60 MILLION OF UNSECURED CONVERTIBLE SENIOR NOTES.NOTES WILL MATURE IN DECEMBER 2021..ENTERED AGREEMENTS FOR SALE OF $60 MILLION OF UNSECURED CONVERTIBLE SENIOR NOTES IN A PRIVATE PLACEMENT WITH 2 "ACCREDITED INVESTORS".INITIAL CONVERSION PRICE FOR NOTES WILL BE $6.32.INTENDS TO USE NET PROCEEDS FROM PLACEMENT TOGETHER TO PARTLY REPAY COMPANY'S OUTSTANDING 6.5% AND 9.5% CONVERTIBLE NOTES DUE IN 2019.NOTES WILL AMORTIZE IN EQUAL MONTHLY PAYMENTS STARTING ON APRIL 1, 2019..  Full Article

Amyris Signs Supply And Distribution Pact With ASR Group
Wednesday, 3 Oct 2018 

Oct 3 (Reuters) - Amyris Inc ::AMYRIS INC - IT HAS SIGNED ITS FIRST SUPPLY AND DISTRIBUTION AGREEMENT FOR ITS NEW, SUGARCANE-DERIVED, ZERO CALORIE SWEETENER WITH ASR GROUP.  Full Article

Amyris Enters Collaboration Agreement With Yifan Pharma
Thursday, 27 Sep 2018 

Sept 27 (Reuters) - Amyris Inc ::AMYRIS ENTERS INTO EXTENSIVE COLLABORATION AGREEMENT WITH LEADING CHINESE PHARMACEUTICAL COMPANY, YIFAN PHARMACEUTICAL CO., LTD..AMYRIS INC - ENTERED INTO A MULTI-YEAR, MULTI-MILLION-DOLLAR AGREEMENT WITH A UNIT OF YIFAN PHARMACEUTICAL CO LTD.AMYRIS INC - COLLABORATION IS STARTING WITH FIRST TARGET IN NUTRITION FOR A KEY MOLECULE TO BE DEVELOPED, SCALED AND MANUFACTURED BY AMYRIS.AMYRIS INC - COMPANIES EXPECT TO BRING TO MARKET 3-5 ADDITIONAL PRODUCTS IN COMING YEARS.AMYRIS INC - UPON SUCCESSFUL COMMERCIALIZATION, CO EXPECTS TO DEVELOP THIS LINE OF BUSINESS INTO $100 MILLION OR MORE OF EXPECTED ANNUAL REVENUE.AMYRIS - EXPECTS PRODUCT BEING COMMERCIALIZED WITHIN CHINESE MARKET AND REST OF GLOBAL MARKET BY 2021 WITH FIRST PRODUCT REVENUE ACHIEVED SAME YEAR.  Full Article

Amyris Files For Potential Sale Of 3.6 Mln Shares By Selling Stockholders
Wednesday, 26 Sep 2018 

Sept 26 (Reuters) - Amyris Inc ::AMYRIS FILES FOR POTENTIAL SALE OF 3.6 MILLION COMMON SHARES BY SELLING STOCKHOLDERS - SEC FILING.  Full Article

Amyris Gets Green Light For Commercial Sales Of New Sweetener
Thursday, 30 Aug 2018 

Aug 30 (Reuters) - Amyris Inc ::AMYRIS GETS GREEN LIGHT FOR COMMERCIAL SALES OF ITS NEW, NATURAL, ZERO-CALORIE SWEETENER.  Full Article

Amyris Announces Secondary Offering Of 7.65 Mln Shares Priced At $6.25 Per Share
Friday, 17 Aug 2018 

Aug 17 (Reuters) - Amyris Inc ::AMYRIS ANNOUNCES PRICING OF SECONDARY OFFERING.SAYS SECONDARY OFFERING OF 7.65 MILLION SHARES PRICED AT $6.25PER SHARE.AMYRIS ANNOUNCES PRICING OF SECONDARY OFFERING.  Full Article

Amyris Announces Non-Dilutive $36 Mln Term Loan
Monday, 2 Jul 2018 

July 2 (Reuters) - Amyris Inc ::AMYRIS ANNOUNCES NON-DILUTIVE $36 MILLION TERM LOAN TO PAY OFF STEGODON AND OTHER SHORT-TERM DEBT MATURITIES.AMYRIS INC - CASH FROM TERM LOAN WILL BE USED TO PAY OFF COMPANY'S STEGODON AND OTHER SHORT-TERM DEBT MATURITIES.AMYRIS INC - TERM LOAN ALSO INCLUDES ADDITIONAL $35 MILLION ACCORDION CREDIT FACILITY WITH OPTION FOR FINANCING CONSTRUCTION OF PRODUCTION FACILITY.  Full Article

Amyris Inc Files For Non-Timely 10-Q - SEC Filing
Wednesday, 16 May 2018 

May 16 (Reuters) - Amyris Inc ::AMYRIS INC FILES FOR NON-TIMELY 10-Q - SEC FILING.  Full Article

Amyris posts Q3 GAAP loss of $1.14 per share
Tuesday, 14 Nov 2017 

Nov 14 (Reuters) - Amyris Inc :Amyris reports another strong quarter of product sales growth and expects strong finish for 2017.Q3 GAAP loss per share $1.14.Q3 revenue $24.2 million versus $26.5 million.Qtrly non-GAAP basic loss per share $‍0.81​.  Full Article